Okusaka et al. reported that in the treatment of hepatocellular carcinoma in Japanese patients, 120 mg BID of tivantinib has been recommended regardless of CYP2C19 phenotype [31]. Here, CYP2C19 is linked to hepatocellular carcinoma.